Filter
641
Text search:
Polymerase
Chain
Reaction
(PCR)
Featured
Recommendations
108
New Publications
207
Language
Document type
No document type
401
Guidelines
104
Studies & Reports
58
Manuals
23
Strategic & Response Plan
22
Fact sheets
14
Situation Updates
6
Resource Platforms
6
Training Material
4
Brochures
1
Infographics
1
Online Courses
1
Countries / Regions
India
30
Global
20
Nigeria
17
Tanzania
17
Congo, Democratic Republic of
16
Ethiopia
16
Africa
16
South Africa
15
Uganda
12
Kenya
12
Liberia
11
Zambia
11
Rwanda
11
Malawi
10
Western and Central Europe
10
Sierra Leone
9
Ghana
9
Bangladesh
8
West and Central Africa
8
East and Southern Africa
7
Nepal
6
Syria
6
Latin America and the Carribbean
6
Zimbabwe
5
Indonesia
5
Namibia
5
Middle East and North Africa
5
Guinea
4
Botswana
4
Lesotho
4
Myanmar / Burma
4
Burkina Faso
3
Senegal
3
Cameroon
3
South Sudan
3
Mozambique
3
Brazil
3
Angola
3
Venezuela
3
Eastern Europe
3
Togo
2
Philippines
2
Germany
2
Cambodia
2
Benin
2
Eswatini/ Swaziland
2
Ukraine
2
Colombia
2
Madagascar
2
Western Pacific Region
2
Côte d’Ivoire / Ivory Coast
1
USA
1
Saudi Arabia
1
Haiti
1
Somalia
1
Pakistan
1
Lebanon
1
Turkey
1
Chad
1
Central African Republic
1
Argentina
1
Dominican Republic
1
Peru
1
North Macedonia
1
Burundi
1
Ecuador
1
Yemen
1
South–East Asia Region
1
Timor Leste/ East Timor
1
Georgia
1
Authors & Publishers
Publication Years
Category
Countries
241
Clinical Guidelines
116
Pharmacy & Technologies
32
Public Health
29
Key Resources
12
Capacity Building
9
Women & Child Health
8
Toolboxes
COVID-19
72
Rapid Response
64
HIV
52
NTDs
49
Ebola
40
TB
37
Zika
26
Cholera
7
Refugee
7
AMR
7
Planetary Health
5
Mental Health
4
Caregiver
4
Polio
3
Conflict
3
Specific Hazards
2
Pharmacy
2
Natural Hazards
1
Global Health Education
1
NCDs
1
Limited coverage of laboratory services and long turnaround times from real-time reverse transcription-polymerase chain reaction (rRT-
...
Este relatório confere uma visão geral estado da epidemia HIV/SIDA em Moçambique e de como tem sido feita a resposta nacional à epidemia. Cobre também as boas práticas neste campo, tal como os principais desafios e acções correctivas.
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are
...
Option B+
PLoS One. 2012; 7(4): e29656.
Published online 2012 Apr 20. doi: 10.1371/journal.pone.0029656
Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec
...
Marburg and Ebola are filoviruses that cause hemorrhage, multiple organ failure, and high mortality rates. Diagnosis is with enzyme-linked immunosorbent assay, polymerase chain
...
On 27 September 2024, the Rwanda Ministry of Health announced the confirmation of Marburg virus disease (MVD). Blood samples taken from people showing symptoms were tested by real-time reverse transcription polymerase
...
Interium guidance, 25 June 2021Timely and accurate diagnostic testing is an essential tool in preventing and controlling the spread of COVID-19. This document describes recommendations for national testing strategies and the use of PCR and rapid ant
...
This document aims to present an algorithm for deciding whom to test and provide guidance on the laboratory tests for Zika virus infection diagnosis in order to support clinical diagnostic and case reporting through surveillance among EU Member States. The algorithm is not intended for clinical man
...
This document presents a consolidated summary of urgent activities
required to advance preparedness, as elaborated in each country's
national plan, with a particular focus on Priority 1 countries. It
presents the estimated requirements, needs, and gaps for each of the
Priority 1 countries and a
...
i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR
ii. A per
...
